Husna Rahim, PharmD & Jennifer Tovar PharmD
Minimizing risks of Drug Reactions Pharmacogenomics. Your Reliable results. How does implementing pharmacogenomics in patient care reduce the incidence of adverse drug reactions?
Pharmacogenomics (PGx) involves the study of how genetic variations can influence drug metabolism, efficacy, and potential side effects. One significant challenge in modern medicine is combating adverse drug reactions (ADRs), which can lead to severe health issues and even fatalities. Minimizing risks of Drug Reactions Pharmacogenomics provides reliable results in reducing ADRs. A wealth of evidence suggests that PGx diagnostics and its integration into routine clinical care can help minimize the risk of ADRs by personalizing treatment decisions according to individual PGx variants.
How does implementing pharmacogenomics in patient care reduce the incidence of adverse drug reactions?
ADRs: leading contributors to morbidity and mortality. Per the Food and Drug Administration (FDA), ADRs are one of the leading contributors to morbidity and mortality in health care (FDA, 2018). As a result, individuals experiencing ADRs are more likely to seek follow-up visits with providers, experience drug failure, and exhibit noncompliance (Dunnenberger et al., 2015 & Haidar et al., 2022). Organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) develop evidence-based guidelines for clinicians to consider a patient’s genetic profile and identify individuals who may be at increased risk of ADRs or require personalized dosing regimens. This supports reliable results from minimizing risks of Drug Reactions Pharmacogenomics.
12 pharmacogenes drive drug response. There are 12 significant pharmacogenes identified as major determinants of drug response and ADRs. Research shows that at least one clinically actionable pharmacogenomic variant will be found in 90% or more of individuals who are genotyped (Dunnenberger et al., 2015, FDA, 2018, & Haidar et al., 2019). This underlines the importance of minimizing risks of Drug Reactions Pharmacogenomics for reliable results. In 2023, a multicenter clinical trial conducted in Europe found that implementing the 12-gene pharmacogenetic panel led to a 30% reduction in the occurrence of ADRs and hospitalizations (Swen et al., 2023). While promising, challenges such as access to testing, interpretation of results, and education of healthcare professionals need to be addressed before widespread adoption.
Integrating PGx testing into clinical practice. Integrating PGx testing into clinical practice has the potential to revolutionize the way medications are prescribed and administered, ensuring minimizing risks of Drug Reactions Pharmacogenomics for reliable results.
Learn more about UGenome’s Personalized Medication Service, ProPEx, or contact UGenome. You can also find case studies for UGenome’s bioinformatics services Metabolite Identification, Bone Metastasis Risk Analysis in Breast Cancer, Survival Analysis with gene signatures in cancer
#ugenome, #ugenomeai, #genetics, #pharmacogenetics, #genomicmedicine, #sequencing, #datascience, #lifesciences, #bioinformatics, #biostatistics, #pharma, #bullpen, #NVIDIAInception, #foundershub,